The objective response rates in the group of patients with wt-KRAS and wt-BRAF tumours were 54.0% (CR 14.7%, PR 39.3%), while in the group of patients with wt-KRAS and mt-BRAF were 38.5% (CR 15.4%, PR 23.1%). The gene discussed is KRAS; the disease is neoplasm.